Drug intelligence / Profile preview

Chronos-X

Development stage: Preclinical
Lead developer: Hartington Pharmaceuticals

Overview

Chronos-X is an early-stage therapeutic candidate being developed by Hartington Pharmaceuticals for the treatment of inherited retinal degeneration. The program is based on a proprietary retinal-restoration platform and is currently supported by computational proof-of-concept work. As of the latest reports, the asset is progressing toward preclinical development and has patents pending.

Other names: Chronos-X

Beyond the preview

Go deeper on Chronos-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chronos-X.

Explore the full profile